Injectable drug delivery is defined as administration of a drug or drugs directly into patient’s blood circulationthrough a delivery device. It is considered as the most common and effective route of administration of most therapeutic agents to achieve the desired quick response. The injectable route of drug administration is expected to continue to be an important delivery system. This has been attributed to reasons that injectable drug delivery system allows administration of drugs with poor oral bioavailability, delivery of the drug at the site of action, targeted drug delivery system. Reduction in the number of injection is achieved by various technologies such as controlled release, targeted delivery and needle free delivery thus overcoming the problems associated with conventional injectable drug delivery. This has also helped in improving quality of therapy. Injectable drug delivery has also proved beneficial in many cases such as unconsciousness, emergency conditions and nausea, due to rapid onset of action. The basic requirement for injectable drug delivery is that it should be pyrogen free, sterile and isotonic.
Major routes for injectable drug delivery include intravenous, intramuscular, intraarterial, intracardiac, subcutaneous, intradermal, intra peritoneal, intrathecal amongst others. Many medications such as antibiotics, peptides and protein, vaccine and gene based drugs, in general are delivered using this route due to their susceptible to enzymatic degradation or poor and inefficient absorption into the systemic circulation due to molecular size and charge,thus leading to their therapeutic effectiveness.Technological advancement, surge of biologics, rising incidences of diseases such as cancer and diabetes and improving patient compliance to injectable drug delivery are some of the major factors driving injectable drug delivery market. However product recalls, patient safety issues, anddevelopment of alternate drug delivery methods, are some of the key deterrents posing a challenge to the growth of global injectable drug delivery market. Manufacturing cost of this drug delivery system is expensive as compared to conventional tablets and capsules. A sudden increase in serum concentration of drug post injection of drug may lead to toxicity. Self injection requires adequate patient training and may initially suffer from pain and infection at the site of injection.
Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-393
The key players contributing to the global injectable drug delivery market include Antares Pharma, Inc., Baxter International, Inc., Becton, Dickinson & Co., Eli Lilly & Company, Hospira, Inc., Novo Nordik A/S, Sanofi SA, Scandinavian Health Limited, Schott AG, Terumo Corporation, Unilife Corporation and Zogenix, Inc.